Rufinamide in patients with Lennox-Gastaut syndrome
Peggy O Clark,1 Patricia A Gibson2 1Cincinnati Children’s Hospital Medical Center, The University of Cincinnati College of Medicine, Cincinnati, OH, 2Epilepsy Information Service, Wake Forest University School of Medicine, Winston-Salem, NC, USA Objectives: Lennox–Gastaut syndrom...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-11-01
|
| Series: | Nursing: Research and Reviews |
| Subjects: | |
| Online Access: | https://www.dovepress.com/rufinamide-in-patients-with-lennox-gastaut-syndrome-peer-reviewed-article-NRR |
| _version_ | 1819022573917175808 |
|---|---|
| author | Clark PO Gibson PA |
| author_facet | Clark PO Gibson PA |
| author_sort | Clark PO |
| collection | DOAJ |
| description | Peggy O Clark,1 Patricia A Gibson2 1Cincinnati Children’s Hospital Medical Center, The University of Cincinnati College of Medicine, Cincinnati, OH, 2Epilepsy Information Service, Wake Forest University School of Medicine, Winston-Salem, NC, USA Objectives: Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy with an onset at the age of ~4 years. LGS is notoriously difficult to manage, as most patients experience multiple seizures per day, despite their concomitant use of several antiepileptic drugs (AEDs). Rufinamide (BANZEL®) is an AED approved by the US Food and Drug Administration for the adjunctive treatment of seizures associated with LGS in pediatric patients aged ≥1 year and in adults. The expert care of nurses knowledgeable in the treatment options for LGS is valuable to patients and caregivers. This review summarizes the existing knowledge on LGS and data from clinical and real-world studies on the use of rufinamide in patients with LGS.Methods: Recent review articles and information from the Epilepsy Foundation Website were reviewed for data on LGS treatment. Primary articles on rufinamide were also selected for review.Results and conclusion: The efficacy and safety of rufinamide have been evaluated in children and adults by using double-blind, open-label, and observational studies. In general, these studies indicate that rufinamide effectively reduces the frequency and severity of multiple seizure types associated with LGS and has tolerable side effects, the most common being vomiting and somnolence. Dosing modifications based on age, weight, and concomitant AED usage are recommended for patients using rufinamide. Keywords: Lennox–Gastaut syndrome, anticonvulsants, rufinamide |
| first_indexed | 2024-12-21T04:25:09Z |
| format | Article |
| id | doaj.art-4ec29a4b19764cf380443c5654fcfd2c |
| institution | Directory Open Access Journal |
| issn | 2230-522X |
| language | English |
| last_indexed | 2024-12-21T04:25:09Z |
| publishDate | 2016-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Nursing: Research and Reviews |
| spelling | doaj.art-4ec29a4b19764cf380443c5654fcfd2c2022-12-21T19:16:04ZengDove Medical PressNursing: Research and Reviews2230-522X2016-11-01Volume 6515929815Rufinamide in patients with Lennox-Gastaut syndromeClark POGibson PAPeggy O Clark,1 Patricia A Gibson2 1Cincinnati Children’s Hospital Medical Center, The University of Cincinnati College of Medicine, Cincinnati, OH, 2Epilepsy Information Service, Wake Forest University School of Medicine, Winston-Salem, NC, USA Objectives: Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy with an onset at the age of ~4 years. LGS is notoriously difficult to manage, as most patients experience multiple seizures per day, despite their concomitant use of several antiepileptic drugs (AEDs). Rufinamide (BANZEL®) is an AED approved by the US Food and Drug Administration for the adjunctive treatment of seizures associated with LGS in pediatric patients aged ≥1 year and in adults. The expert care of nurses knowledgeable in the treatment options for LGS is valuable to patients and caregivers. This review summarizes the existing knowledge on LGS and data from clinical and real-world studies on the use of rufinamide in patients with LGS.Methods: Recent review articles and information from the Epilepsy Foundation Website were reviewed for data on LGS treatment. Primary articles on rufinamide were also selected for review.Results and conclusion: The efficacy and safety of rufinamide have been evaluated in children and adults by using double-blind, open-label, and observational studies. In general, these studies indicate that rufinamide effectively reduces the frequency and severity of multiple seizure types associated with LGS and has tolerable side effects, the most common being vomiting and somnolence. Dosing modifications based on age, weight, and concomitant AED usage are recommended for patients using rufinamide. Keywords: Lennox–Gastaut syndrome, anticonvulsants, rufinamidehttps://www.dovepress.com/rufinamide-in-patients-with-lennox-gastaut-syndrome-peer-reviewed-article-NRRLennox Gastaut Syndromeanticonvulsantsrufinamide |
| spellingShingle | Clark PO Gibson PA Rufinamide in patients with Lennox-Gastaut syndrome Nursing: Research and Reviews Lennox Gastaut Syndrome anticonvulsants rufinamide |
| title | Rufinamide in patients with Lennox-Gastaut syndrome |
| title_full | Rufinamide in patients with Lennox-Gastaut syndrome |
| title_fullStr | Rufinamide in patients with Lennox-Gastaut syndrome |
| title_full_unstemmed | Rufinamide in patients with Lennox-Gastaut syndrome |
| title_short | Rufinamide in patients with Lennox-Gastaut syndrome |
| title_sort | rufinamide in patients with lennox gastaut syndrome |
| topic | Lennox Gastaut Syndrome anticonvulsants rufinamide |
| url | https://www.dovepress.com/rufinamide-in-patients-with-lennox-gastaut-syndrome-peer-reviewed-article-NRR |
| work_keys_str_mv | AT clarkpo rufinamideinpatientswithlennoxgastautsyndrome AT gibsonpa rufinamideinpatientswithlennoxgastautsyndrome |